The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose nearly 9% intraday. As of press release, it rose 5.58% to HK$6.05, with a turnover of HK$9.829,800.

According to the news, Goli Pharmaceuticals announced that its most comprehensive weekly oral peptide line for the treatment of obesity has obtained positive preclinical data. The pipeline covers all four proven targets and includes several first-of-its-kind fixed-dose formulations.

The announcement mentioned that the oral insulin receptor agonist polypeptide Asc36o is the fastest progressing drug candidate in this pipeline, and phase I studies are currently being conducted in the US. Asc36o shows a half-life of about 7 days and oral bioavailability of 6% to 8% in non-human primates, supporting weekly oral administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.